FDA Clearance Tracker · P940035-S017
NMP22 BladderChek Test
Last checked: Nov 20, 2026Latest source record: Jul 12, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jul 12, 2022
Approved
Time to decision
154 days
Received Feb 8, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P940035-S017
- Device name
- NMP22 BladderChek Test
- Applicant
- Abbott Diagnostics Scarborough, Inc.
- Applicant location
- Scarborough, ME
- Received
- Feb 8, 2022
- Decided
- Jul 12, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P940035
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to manufacture Alere NMP22 BladderChek Test under Abbott Diagnostics Scarborough, Inc.s new brand name: NMP22 BladderChek Test.
Source documents
Other decisions for Abbott Diagnostics Scarborough, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262747 · Decided Aug 31, 2026 · 28 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.